← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Revenue decreased 13.2% to $593.0K, while Net income decreased 0.9% to ($45.9M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue $593.0KWatch
- Profitability — Net income ($45.9M)Watch
- Cash generation — Free cash flow ($38.0M)Note
- Accounting — Formula distress score · no manipulation flag · earnings quality greyWatch
- Insiders — 0 buys; 0 sells in 365 daysNote
- Capital — Comparable payout data unavailableNote
Business
Cardiff Oncology, Inc.: We will need to raise substantial additional capital to develop and commercialize onvansertib, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.
Leadership changes
From Cardiff Oncology, Inc.'s own filings, the day they're filed.
- Ajay Aggarwal · Chief Operating Officer · appointmenteff. 2026-04-27
- Mani Mohindru · President · appointmenteff. 2026-04-09
- Josh Muntner · Chief Financial Officer · appointmenteff. 2026-04-06
Latest filings
- 8-K · Company announcement2026-08-11
- 10-Q · Quarterly report2026-08-11
- 8-K · Company announcement2026-07-16
- 8-K · Company announcement2026-06-11
- 8-K · Company announcement2026-06-03
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Cardiff Oncology, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.